Whereas the first-generation XPO1 inhibitor, Selinexor, was tested in GBM cells, no data so far are available for the more efficient second-generation XPO1 inhibitor, Eltanexor, which should be tested in GBM cell lines and in glioblastoma stem-like cells (GSCs), which are the most resistant to therapeutic interventions and are considered as the origin of recurrent glioblastoma after acquiring therapy resistance. The gene discussed is XPO1; the disease is glioblastoma.